GlassScriptPhysician profile
Maria Mcpherson
NPI 1659374809
$3,137.19
in general payments reported to CMS, 2019-2025
20 companies · $712 in 2025
The $712 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $161 · 2021: $89.67 · 2022: $523 · 2023: $554 · 2024: $689 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $380.35 | 2019-2025 | Rocklatan, Clareon, Eysuvis |
| Bausch & Lomb Americas INC. | $369.74 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $354.73 | 2022-2025 | |
| Oyster Point Pharma, INC. | $271.52 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $271.06 | 2023-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Biotissue Holdings INC. | $197.85 | 2025 | |
| Allergan, INC. | $195.10 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $172.37 | 2022-2024 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $161.45 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $161.15 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $139.40 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.62 | 2019-2021 | |
| Shire North American Group INC | $83.70 | 2019 | |
| Aerie Pharmaceuticals, INC. | $76.40 | 2019-2020 | |
| Thea Pharma INC. | $55.17 | 2023-2025 | Iyuzeh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $42.24 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $34.79 | 2022 | |
| Amgen INC. | $24.05 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Mcpherson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.